Inhibitors of the human endogenous retrovirus-H long-terminal repeat-associating protein 2 (HHLA2) are promising treatments that could help patients with primary resistance to anti-PD1/PDL-1, such as in melanoma and hepatic cholangiocarcinoma [121]. The gene discussed is PDCD1; the disease is melanoma.